With the Consortium of Multiple Sclerosis Centers (CMSC) 2016 fast approaching, Multiple Sclerosis News Today sat down with a man of far-reaching interest in multiple sclerosis (MS) — Dr. Rick Munschauer, Vice President of Medical Affairs, Neurology and Immunology at EMD Serono — to discuss why the 30th annual meeting is important to the pharmaceutical company that sees patient support and education as a prime mission.
EMD Serono, a biopharmaceutical company founded in Italy and later acquired by Merck KGaA, Darmstadt, Germany, belongs to one of the oldest pharmaceutical firms in the world. For more than 40 years, EMD Serono has focused solely on specialty care, including MS treatment.
The company’s MS drug Rebif (interferon beta-1a) launched on the market in 2002 and since then, EMD Serono has continued to gather information of its effects and safety, and to improve the drug’s delivery. The company’s research brought other MS compounds to clinical development as well. Currently, it is in preparatory mode for seeking approval for cladribine tablets from the European Medicines Agency (EMA).
But what makes EMD Serono stand out from most pharmaceutical businesses is at the heart of the company’s MS LifeLines patient support and education service. The program connects MS patients with experts in the field, healthcare support, financial advice and each other.
Munschauer, who joined EMD Serono a little over a year ago, has an impressive history in the world of neurology and MS having worked for and been a leader in academic institutions, pharmaceutical businesses, and research for more than 30 years.
CMSC 2016, June 1 – 4, at the Gaylord National Resort and Convention Center in National Harbor, Md., will host MS researchers and clinicians worldwide for three days of high level symposiums.
Munschauer explained to Multiple Sclerosis News Today why the meeting is important to EMD Serono. Below, is the question and answer interview.
Q: EMD Serono has participated in CMSC meetings in past years, and this year is no exception. Why?
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?